Ziyuglycoside I (ZGS1) is a promising drug candidate for the treatment of leucopenia.\nCurrently, information on ZGS1 and its in vivo metabolite ziyuglycoside II (ZGS2) is limited.\nThe objective of this study was to investigate the pharmacokinetics, tissue distribution, and excretion\nof ziyuglycoside I (ZGS1) and its metabolite ziyuglycoside II (ZGS2) in rats. In our study, a simple\nand sensitive high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method\nwas established for simultaneous determination of ZGS1 and its metabolite for Sprague-Dawley rat\npharmacokinetics studies. The method was validated following internationally-approved guidelines.\nThe results presented in this study indicated that subcutaneous administration of ZGS1 prolonged\nits extension time and increased the area under the curve (AUC0ââ?¬â??t) of ZGS2 during 0 to t minutes.\nIn summary, in this study, the pharmacokinetic characteristics of ZGS1 and its metabolite ZGS2\nwere defined and its tissue distribution, and excretion in rats were described. Our finding may be\nbeneficial for leucopenia drug that focus on ZGS1.
Loading....